The objective of this post market clinical investigation is to evaluate the clinical effectiveness of a minimally invasive vertebral augmentation procedure, Radiofrequency-Targeted Vertebral Augmentation (RF-TVA) as compared to non-operative management (NOM) for the treatment of appropriately diagnosed acute (≤ 8 weeks) painful osteoporotic vertebral compression fractures (VCF).
This is a multi-center, prospective, randomized, post marketing clinical trial designed to evaluate the clinical effectiveness of a minimally invasive procedure, Radiofrequency-Targeted Vertebral Augmentation (RF-TVA), compared to Non Operative Management (NOM) for the treatment of appropriately diagnosed, acute (≤ 8 weeks), painful, osteoporotic vertebral compression fractures. Eligible subjects will be randomly allocated to receive either RF-TVA or NOM in a 1:1 randomization ratio. Subjects will be followed for 12 months post procedure. Primary effectiveness will be determined by comparing the Visual Analogue Scale for each treatment group for back pain from the baseline to the 1-month post procedure visit and between treatment groups at 1-month. Up to 15 sites will participate in this trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Vertebral Augmentation with the STABILIT Vertebral Augmentation System
Conservative Care
Washington University - Mallinckrodt Institute of Radiology
St Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center, Department of Radiology
Lebanon, New Hampshire, United States
Winthrop University Hospital, Department of Radiology
Mineola, New York, United States
Montefiore Hospital/Einstein Medical School, Department of Radiology
Improvement in back pain from baseline at the 1 month follow-up visit as measured by the Visual Analog Scale.
Time frame: 1 month
Change in VAS from baseline at the 3, 6, and 12 month follow-up visits.
Time frame: 3, 6, and 12 months
Change in Roland-Morris Questionnaire (RDQ) from baseline at the 1, 3, 6, and 12 month follow-up visits.
Time frame: 1,3,6,12 months
Change in SF-36 physical component score from baseline at the 1, 3, 6, and 12 month follow-up visits.
Time frame: 1,3,6,12 months
Change in IOF Quality of Life Questionnaire from baseline at the 1, 3, 6, and 12 month follow-up visits.
Time frame: 1,3,6,12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Bronx, New York, United States
Penn State Hershey Medical Center, Department of Radiology
Hershey, Pennsylvania, United States
Swedish Neuroscience Institute, Cherry Hill Campus, Department of Neurosurgery
Seattle, Washington, United States